Halozyme Therapeutics has appointed James "Jim" Daly to its Board of Directors, bringing over 30 years of biopharmaceutical commercial leadership experience. Daly's background includes senior roles at Incyte, Amgen, and GlaxoSmithKline, with a strong track record in launching successful therapies. His expertise will support Halozyme's growth in subcutaneous drug delivery technologies like ENHANZE, Hypercon, and Aerocon. This move aims to enhance Halozyme's ability to expand its innovative drug delivery solutions and improve patient treatment experiences.
Halozyme's board appointment news is presented here with relevant market data for context. For readers following the Health sector, 39 of 100 US stocks traded on Pluang rose while 59 fell as of Oct 01, 2026 02:11 WIB. Notable movers include FLNA at USD 0.87 with a 5.43% decline, CLPT at USD 12.36 with a 4.97% gain, and HIMS at USD 30.11 with a 4.91% increase, reflecting varied investor activity and typical hold times on the platform.
Loans backed by Bitcoin and stablecoins have become eligible within Fannie Mae's mortgage framework through administrative decisions rather than market-driven validation. This development is significant as it represents a major step for crypto credit...
Rosen Law Firm has filed a class action lawsuit against Better Home & Finance Holding Company for allegedly making false and misleading statements about its $1 billion monthly funded volume target during March to May 2026. The lawsuit claims the comp...
HireQuest Inc. is rated Buy due to its asset-light staffing model that cuts costs and boosts profitability. The stock has surged over 80% year-to-date, driven by strong manufacturing hiring and a solid pipeline of national accounts with visibility in...
Royce Global Trust, a closed-end fund focusing on global small- and mid-cap equities using a value approach, reported a one-year total return of 21.7% as of August 31, 2026. The fund invests at least 80% of its assets in equity securities, with a sig...
Advanced Micro Devices (AMD) has been upgraded to a Buy rating following its $8.2 billion acquisition of World Labs, which enhances its capabilities in frontier and physical AI. The deal strengthens AMD's AI ecosystem, brings in top talent, and posit...
